As Bayer previously highlighted in their topline data announcement, the FINEARTS trial met its primary endpoint, with use of finerenone associated with a statistically significant 16% relative reduction in rate of primary outcome events compared with placebo therapy (rate ratio [RR], 0.84
Cell Host Microbe 8, 4454
Retatrutide will likely cost slightly more at launch given its added complexity, but manufacturer savings programs could bring both to similar out-of-pocket costs for eligible patients
In healthy individuals, less than 2% of dietary tryptophan is converted to NAD in the kynurenine pathway (40)
Many UMR plans also require prior authorization for certain medications (especially newer or more expensive drugs)
2,4 Wegovy and Mounjaro also have cardiovascular outcomes work that retatrutide hasnt completed yet